{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T05:55:27Z","timestamp":1764568527614,"version":"3.46.0"},"reference-count":109,"publisher":"Bentham Science Publishers Ltd.","issue":"15","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Diabetes mellitus is a disease characterised by elevated blood glucose levels, with its major\nsubtypes being type 1 (immune-mediated) and type 2 (lifestyle-related) diabetes. Medical treatment\nfor diabetes requires patients to perform subcutaneous insulin injections since oral insulin faces\nproblems with gastric breakdown. Nano-sized insulin delivery systems show great potential for\noral usage because they protect the insulin molecule from enzymatic breakdown and enhance its\nabsorption rates through the digestive system. The review article investigates the utilisation of insulin-\nloaded nanoparticles as an advanced treatment method for diabetes management. The data evaluates\ninsulin-loaded nanoparticles for their impact on stability enhancement as well as their protective\nfunctions and improved oral bioavailability potential. The research reviewed the relevant literature\non insulin-loaded nanoparticles as a treatment method for diabetes. The research articles were\nobtained through databases including ScienceDirect, Scopus, PubMed and Google Scholar. Studies\nabout incorporating insulin with nanoparticles and their bioavailability features and therapeutic potential\nwere analysed. The review demonstrates that insulin-loaded nanoparticles markedly improve\ninsulin stability, bioavailability, and absorption, overcoming the challenges associated with oral insulin\ndelivery. Diverse nanoparticle compositions, encompassing polymeric and lipid-based carriers,\nexhibit encouraging outcomes in preclinical investigations. Despite existing limitations in\nlarge-scale production and clinical application, nanotechnology presents a revolutionary method for\ndiabetes treatment. Additional research and clinical studies are necessary to validate insulin-loaded\nnanoparticles as a feasible, patient-friendly substitute for traditional insulin therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113895575398397250827102455","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T11:51:21Z","timestamp":1758196281000},"page":"1186-1198","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Revolutionizing Diabetes Treatment with Insulin-loaded Nanoparticles"],"prefix":"10.2174","volume":"25","author":[{"given":"Jatin","family":"Vats","sequence":"first","affiliation":[{"name":"Hindu College of Pharmacy, Sonipat, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjali","family":"Rana","sequence":"additional","affiliation":[{"name":"Hindu College of Pharmacy, Sonipat, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajesh","family":"Chauhan","sequence":"additional","affiliation":[{"name":"Hindu College of Pharmacy, Sonipat, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivam","family":"Rajput","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Medical and Allied Sciences,Galgotias University, Greater Noida, Uttar Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2874-6149","authenticated-orcid":true,"given":"Rishabha","family":"Malviya","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Medical and Allied Sciences,Galgotias University, Greater Noida, Uttar Pradesh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chetan","family":"Vashist","sequence":"additional","affiliation":[{"name":"Hindu College of Pharmacy, Sonipat, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun","family":"Mittal","sequence":"additional","affiliation":[{"name":"Hindu College of Pharmacy, Sonipat, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sathvik Belagodu","family":"Sridhar","sequence":"additional","affiliation":[{"name":"RAK College of Pharmacy, RAK Medical &amp; Health SciencesUniversity, Ras Al Khaimah, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.diabres.2018.02.023","volume":"138","author":"Cho N.H.","year":"2018","unstructured":"Cho N.H.; Shaw J.E.; Karuranga S.; Huang Y.; da Rocha Fernandes J.D.; Ohlrogge A.W.; Malanda B.; Diabetes Atlas I.D.F.; IDF diabetes atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract  2018,138,271-281","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.2337\/dc18-S008","volume":"41","year":"2018","unstructured":"8. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes\u20142018. Diabetes Care  2018,41(Suppl. 1),S73-S85","journal-title":"Diabetes Care"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"17016","DOI":"10.1038\/nrdp.2017.16","volume":"3","author":"Katsarou A.","year":"2017","unstructured":"Katsarou A.; Gudbj\u00f6rnsdottir S.; Rawshani A.; Dabelea D.; Bonifacio E.; Anderson B.J.; Jacobsen L.M.; Schatz D.A.; Lernmark \u00c5.; Type 1 diabetes mellitus. Nat Rev Dis Primers  2017,3(1),17016","journal-title":"Nat Rev Dis Primers"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"100158","DOI":"10.1016\/j.medidd.2023.100158","volume":"18","author":"Rajput S.","year":"2023","unstructured":"Rajput S.; Kumar Sharma P.; Malviya R.; Fluid mechanics in circulating tumour cells: Role in metastasis and treatment strategies. Med Drug Discov  2023,18,100158","journal-title":"Med Drug Discov"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1136\/postgradmedj-2022-141651","volume":"99","author":"Russell-Jones D.","year":"2023","unstructured":"Russell-Jones D.; Bawlchhim Z.; Discovery of insulin 100 years on. Postgrad Med J  2023,99(1173),661-668","journal-title":"Postgrad Med J"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nature01667","volume":"423","author":"Puigserver P.","year":"2003","unstructured":"Puigserver P.; Rhee J.; Donovan J.; Walkey C.J.; Yoon J.C.; Oriente F.; Kitamura Y.; Altomonte J.; Dong H.; Accili D.; Spiegelman B.M.; Insulin-regulated hepatic gluconeogenesis through FOXO1\u2013PGC-1\u03b1 interaction. Nature  2003,423(6939),550-555","journal-title":"Nature"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"31484","DOI":"10.1074\/jbc.M109.033936","volume":"284","author":"Liu H.Y.","year":"2009","unstructured":"Liu H.Y.; Han J.; Cao S.Y.; Hong T.; Zhuo D.; Shi J.; Liu Z.; Cao W.; Hepatic autophagy is suppressed in the presence of insulin resistance and hyperinsulinemia: Inhibition of FoxO1-dependent expression of key autophagy genes by insulin. J Biol Chem  2009,284(45),31484-31492","journal-title":"J Biol Chem"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s41664-024-00302-5","volume":"8","author":"Fagan A.","year":"2024","unstructured":"Fagan A.; Bateman L.M.; O\u2019Shea J.P.; Crean A.M.; Elucidating the degradation pathways of human insulin in the solid state. J Anal Test  2024,8(3),288-299","journal-title":"J Anal Test"},{"year":"2021","author":"Girardot S.","key":"ref=9","unstructured":"Girardot S.; In vitro and in silico approach of continuous subcutaneous insulin infusion system reliability.. Doctoral dissertation, Sorbonne Universit\u00e9  2021"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2337\/diab.37.1.81","volume":"37","author":"Fukuda M.","year":"1988","unstructured":"Fukuda M.; Tanaka A.; Tahara Y.; Ikegami H.; Yamamoto Y.; Kumahara Y.; Shima K.; Correlation between minimal secretory capacity of pancreatic \u03b2-cells and stability of diabetic control. Diabetes  1988,37(1),81-88","journal-title":"Diabetes"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3389\/fendo.2013.00037","volume":"4","author":"Cerf M.E.","year":"2013","unstructured":"Cerf M.E.; Beta cell dysfunction and insulin resistance. Front Endocrinol  2013,4,37","journal-title":"Front Endocrinol"},{"key":"ref=12","first-page":"57","volume":"45","author":"Linn T.","year":"1994","unstructured":"Linn T.; Ebner K.; Schneider K.; Discher T.; Kreuter J.; Raptis G.; Laube H.; A One-year study of newly Manifested Type-I Diabetes- mellitus under tight glucose control. Med Welt  1994,45(3),57-61","journal-title":"Med Welt"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1093\/clinchem\/48.12.2270","volume":"48","author":"Rosenfeld L.","year":"2002","unstructured":"Rosenfeld L.; Insulin: Discovery and controversy. Clin Chem  2002,48(12),2270-2288","journal-title":"Clin Chem"},{"key":"ref=14","first-page":"378048","volume":"2014","author":"Verma A.","year":"2014","unstructured":"Verma A.; Kumar N.; Malviya R.; Sharma P.K.; Emerging trends in non-invasive insulin delivery. J Pharm  2014,2014(1),378048","journal-title":"J Pharm"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"813","DOI":"10.7326\/M20-2470","volume":"173","author":"Doyle-Delgado K.","year":"2020","unstructured":"Doyle-Delgado K.; Chamberlain J.J.; Shubrook J.H.; Skolnik N.; Trujillo J.; Pharmacologic approaches to glycemic treatment of type 2 diabetes: Synopsis of the 2020 American diabetes association\u2019s standards of medical care in diabetes clinical guideline. Ann Intern Med  2020,173(10),813-821","journal-title":"Ann Intern Med"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1800458","DOI":"10.1002\/mabi.201800458","volume":"19","author":"Baghban Taraghdari Z.","year":"2019","unstructured":"Baghban Taraghdari Z.; Imani R.; Mohabatpour F.; A review on bioengineering approaches to insulin delivery: A pharmaceutical and engineering perspective. Macromol Biosci  2019,19(4),1800458","journal-title":"Macromol Biosci"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1208\/s12249-017-0725-1","volume":"18","author":"Kondiah P.P.D.","year":"2017","unstructured":"Kondiah P.P.D.; Choonara Y.E.; Tomar L.K.; Tyagi C.; Kumar P.; du Toit L.C.; Marimuthu T.; Modi G.; Pillay V.; Development of a gastric absorptive, immediate responsive, oral protein-loaded versatile polymeric delivery system. AAPS PharmSciTech  2017,18(7),2479-2493","journal-title":"AAPS PharmSciTech"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.2174\/0113894501258059231103072025","volume":"24","author":"Rajput S.","year":"2023","unstructured":"Rajput S.; Sharma P.K.; Malviya R.; Biomarkers and treatment strategies for breast cancer recurrence. Curr Drug Targets  2023,24(15),1209-1220","journal-title":"Curr Drug Targets"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.colsurfb.2009.09.001","volume":"75","author":"Kumari A.","year":"2010","unstructured":"Kumari A.; Yadav S.K.; Yadav S.C.; Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces  2010,75(1),1-18","journal-title":"Colloids Surf B Biointerfaces"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1021\/la051982u","volume":"22","author":"Joshi H.M.","year":"2006","unstructured":"Joshi H.M.; Bhumkar D.R.; Joshi K.; Pokharkar V.; Sastry M.; Gold nanoparticles as carriers for efficient transmucosal insulin delivery. Langmuir  2006,22(1),300-305","journal-title":"Langmuir"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.3109\/03639041003695089","volume":"36","author":"Zhao X.","year":"2010","unstructured":"Zhao X.; Zu Y.; Zu S.; Wang D.; Zhang Y.; Zu B.; Insulin nanoparticles for transdermal delivery: Preparation and physicochemical characterization and in vitro evaluation. Drug Dev Ind Pharm  2010,36(10),1177-1185","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1111\/jphp.12607","volume":"68","author":"Wong C.Y.","year":"2016","unstructured":"Wong C.Y.; Martinez J.; Dass C.R.; Oral delivery of insulin for treatment of diabetes: Status quo, challenges and opportunities. J Pharm Pharmacol  2016,68(9),1093-1108","journal-title":"J Pharm Pharmacol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1046\/j.1523-1755.2003.00712.x","volume":"63","author":"Adler A.I.","year":"2003","unstructured":"Adler A.I.; Stevens R.J.; Manley S.E.; Bilous R.W.; Cull C.A.; Holman R.R.; Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int  2003,63(1),225-232","journal-title":"Kidney Int"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-bioeng-071811-150124","volume":"14","author":"Albanese A.","year":"2012","unstructured":"Albanese A.; Tang P.S.; Chan W.C.W.; The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng  2012,14(1),1-16","journal-title":"Annu Rev Biomed Eng"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1039\/C1CS15237H","volume":"41","author":"Dreaden E.C.","year":"2012","unstructured":"Dreaden E.C.; Alkilany A.M.; Huang X.; Murphy C.J.; El-Sayed M.A.; The golden age: Gold nanoparticles for biomedicine. Chem Soc Rev  2012,41(7),2740-2779","journal-title":"Chem Soc Rev"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1039\/c2cs15327k","volume":"41","author":"Elsabahy M.","year":"2012","unstructured":"Elsabahy M.; Wooley K.L.; Design of polymeric nanoparticles for biomedical delivery applications. Chem Soc Rev  2012,41(7),2545-2561","journal-title":"Chem Soc Rev"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1039\/c2cs15344k","volume":"41","author":"Kamaly N.","year":"2012","unstructured":"Kamaly N.; Xiao Z.; Valencia P.M.; Radovic-Moreno A.F.; Farokhzad O.C.; Targeted polymeric therapeutic nanoparticles: Design, development and clinical translation. Chem Soc Rev  2012,41(7),2971-3010","journal-title":"Chem Soc Rev"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"100174","DOI":"10.4172\/2329-6631.1000174","volume":"6","author":"Mehmood A.","year":"2017","unstructured":"Mehmood A.; Ghafar H.; Yaqoob S.; Gohar U.F.; Ahmad B.; Mesoporous silica nanoparticles: A review. J Dev Drugs  2017,6(2),100174","journal-title":"J Dev Drugs"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/978-1-61779-052-2_21","volume":"726","author":"Eifler A.C.","year":"2011","unstructured":"Eifler A.C.; Thaxton, CS Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study. Methods Mol Biol  2011,726,325-338","journal-title":"Methods Mol Biol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1007\/s00125-016-3996-2","volume":"59","author":"Csajb\u00f3k \u00c9.A.","year":"2016","unstructured":"Csajb\u00f3k \u00c9.A.; Tam\u00e1s G.; Cerebral cortex: A target and source of insulin? Diabetologia  2016,59(8),1609-1615","journal-title":"Diabetologia"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.mam.2015.01.004","volume":"42","author":"Kaufman B.A.","year":"2015","unstructured":"Kaufman B.A.; Li C.; Soleimanpour S.A.; Mitochondrial regulation of \u03b2-cell function: Maintaining the momentum for insulin release. Mol Aspects Med  2015,42,91-104","journal-title":"Mol Aspects Med"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"E38","DOI":"10.1152\/ajpendo.00227.2017","volume":"315","author":"Yang B.Y.","year":"2018","unstructured":"Yang B.Y.; Zhai G.; Gong Y.L.; Su J.Z.; Peng X.Y.; Shang G.H.; Han D.; Jin J.Y.; Liu H.K.; Du Z.Y.; Yin Z.; Xie S.Q.; Different physiological roles of insulin receptors in mediating nutrient metabolism in zebrafish. Am J Physiol Endocrinol Metab  2018,315(1),E38-E51","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1042\/BST0330350","volume":"33","author":"Farese R.V.","year":"2005","unstructured":"Farese R.V.; Sajan M.P.; Standaert M.L.; Atypical protein kinase C in insulin action and insulin resistance. Biochem Soc Trans  2005,33(2),350-353","journal-title":"Biochem Soc Trans"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nrm1837","volume":"7","author":"Taniguchi C.M.","year":"2006","unstructured":"Taniguchi C.M.; Emanuelli B.; Kahn C.R.; Critical nodes in signalling pathways: Insights into insulin action. Nat Rev Mol Cell Biol  2006,7(2),85-96","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1007\/s00125-020-05192-7","volume":"63","author":"Vasiljevi\u0107 J.","year":"2020","unstructured":"Vasiljevi\u0107 J.; Torkko J.M.; Knoch K.P.; Solimena M.; The making of insulin in health and disease. Diabetologia  2020,63(10),1981-1989","journal-title":"Diabetologia"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/jid.2010.103","volume":"130","author":"Davidovici B.B.","year":"2010","unstructured":"Davidovici B.B.; Sattar N.; J\u00f6rg P.C.; Puig L.; Emery P.; Barker J.N.; van de Kerkhof P.; St\u00e5hle M.; Nestle F.O.; Girolomoni G.; Krueger J.G.; Psoriasis and systemic inflammatory diseases: Potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol  2010,130(7),1785-1796","journal-title":"J Invest Dermatol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"115320","DOI":"10.1016\/j.addr.2024.115320","volume":"209","author":"Sun L.","year":"2024","unstructured":"Sun L.; Wang D.; Feng K.; Zhang J.A.; Gao W.; Zhang L.; Cell membrane-coated nanoparticles for targeting carcinogenic bacteria. Adv Drug Deliv Rev  2024,209,115320","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/9289812","volume":"2022","author":"Wang B.","year":"2022","unstructured":"Wang B.; Yang Y.; Li X.; Interaction of hypertension and insulin resistance exacerbates the occurrence of diabetes mellitus in healthy individuals. J Diabetes Res  2022,2022(1),1-7","journal-title":"J Diabetes Res"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.molmet.2018.10.008","volume":"19","author":"Haywood N.J.","year":"2019","unstructured":"Haywood N.J.; Slater T.A.; Matthews C.J.; Wheatcroft S.B.; The insulin like growth factor and binding protein family: Novel therapeutic targets in obesity and diabetes. Mol Metab  2019,19,86-96","journal-title":"Mol Metab"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1002\/ptr.6885","volume":"35","author":"Semwal D.K.","year":"2021","unstructured":"Semwal D.K.; Kumar A.; Aswal S.; Chauhan A.; Semwal R.B.; Protective and therapeutic effects of natural products against diabetes mellitus via regenerating pancreatic \u03b2 \u2010cells and restoring their dysfunction. Phytother Res  2021,35(3),1218-1229","journal-title":"Phytother Res"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1146\/annurev-physiol-030212-183754","volume":"75","author":"Rorsman P.","year":"2013","unstructured":"Rorsman P.; Braun M.; Regulation of insulin secretion in human pancreatic islets. Annu Rev Physiol  2013,75(1),155-179","journal-title":"Annu Rev Physiol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"E308","DOI":"10.1152\/ajpendo.1999.277.2.e308","volume":"277","author":"Beauloye V.","year":"1999","unstructured":"Beauloye V.; Muaku S.; Lause P.; Portetelle D.; Renaville R.; Stroobants A.; Ketelslegers J.; Maiter D.; Monoclonal antibodies to growth hormone (GH) prolong liver GH binding and GH-induced IGF-I\/IGFBP-3 synthesis. Am J Physiol Endocrinol Metab  1999,277(2),E308-E315","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.ymgme.2011.08.026","volume":"104","author":"McCulloch L.J.","year":"2011","unstructured":"McCulloch L.J.; van de Bunt M.; Braun M.; Frayn K.N.; Clark A.; Gloyn A.L.; GLUT2 (SLC2A2) is not the principal glucose transporter in human pancreatic beta cells: Implications for understanding genetic association signals at this locus. Mol Genet Metab  2011,104(4),648-653","journal-title":"Mol Genet Metab"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jcjo.2024.01.018","volume":"59","author":"Rajput S.","year":"2024","unstructured":"Rajput S.; Malviya R.; Uniyal P.; Advancements in the diagnosis, prognosis, and treatment of retinoblastoma. Can J Ophthalmol  2024,59(5),281-299","journal-title":"Can J Ophthalmol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/j.1463-1326.2011.01373.x","volume":"13","author":"Kampmann U.","year":"2011","unstructured":"Kampmann U.; Hoeyem P.; Mengel A.; Schmitz O.; Rungby J.; Orskov L.; M\u00f8ller N.; Insulin dose-response studies in severely insulin-resistant type 2 diabetes-evidence for effectiveness of very high insulin doses. Diabetes Obes Metab  2011,13(6),511-516","journal-title":"Diabetes Obes Metab"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s00125-004-1527-z","volume":"47","author":"Clarke P.M.","year":"2004","unstructured":"Clarke P.M.; Gray A.M.; Briggs A.; Farmer A.J.; Fenn P.; Stevens R.J.; Matthews D.R.; Stratton I.M.; Holman R.R.; A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia  2004,47(10),1747-1759","journal-title":"Diabetologia"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"S394","DOI":"10.2337\/diabetes.51.2007.S394","volume":"51","author":"Matschinsky F.M.","year":"2002","unstructured":"Matschinsky F.M.; Regulation of pancreatic \u03b2-cell glucokinase: From basics to therapeutics. Diabetes  2002,51(Suppl. 3),S394-S404","journal-title":"Diabetes"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1210\/en.2008-1557","volume":"150","author":"Lamontagne J.","year":"2009","unstructured":"Lamontagne J.; Pepin \u00c9.; Peyot M.L.; Joly \u00c9.; Ruderman N.B.; Poitout V.; Madiraju S.R.M.; Nolan C.J.; Prentki M.; Pioglitazone acutely reduces insulin secretion and causes metabolic deceleration of the pancreatic \u03b2-cell at submaximal glucose concentrations. Endocrinology  2009,150(8),3465-3474","journal-title":"Endocrinology"},{"key":"ref=49","first-page":"214","volume":"153","author":"Guti\u00e9rrez-Rodelo C.","year":"2017","unstructured":"Guti\u00e9rrez-Rodelo C.; Roura-Guiberna A.; Olivares-Reyes J.A.; Molecular mechanisms of insulin resistance: An update. Gac Med Mex  2017,153(2),214-228","journal-title":"Gac Med Mex"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.2337\/diacare.24.12.2030","volume":"24","author":"Kaufman F.R.","year":"2001","unstructured":"Kaufman F.R.; Gibson L.C.; Halvorson M.; Carpenter S.; Fisher L.K.; Pitukcheewanont P.; A pilot study of the continuous glucose monitoring system: Clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. Diabetes Care  2001,24(12),2030-2034","journal-title":"Diabetes Care"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"A123","DOI":"10.2337\/diabetes.51.2.A123","volume":"51","author":"Kelly J.L.","year":"2002","unstructured":"Kelly J.L.; Hirsch I.B.; Trence D.L.; Rapid decrease in clinically significant hypoglycemia with insulin glargine. Diabetes  2002,51(2),A123","journal-title":"Diabetes"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"eade8647","DOI":"10.1126\/scitranslmed.ade8647","volume":"16","author":"Lu Y.","year":"2024","unstructured":"Lu Y.; Xu J.; Li Y.; Wang R.; Dai C.; Zhang B.; Zhang X.; Xu L.; Tao Y.; Han M.; Guo R.; Wu Q.; Wu L.; Meng Z.; Tan M.; Li J.; DRAK2 suppresses autophagy by phosphorylating ULK1 at Ser 56 to diminish pancreatic \u03b2 cell function upon overnutrition. Sci Transl Med  2024,16(733),eade8647","journal-title":"Sci Transl Med"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/9781118924853.ch13","author":"Roden M.","year":"2017","unstructured":"Roden M.; Petersen K.; Shulman G.; Insulin resistance in type 2 diabetes. Textbook of Diabetes  2017,174-186","journal-title":"Textbook of Diabetes"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3390\/ijms20061351","volume":"20","author":"Kostov K.","year":"2019","unstructured":"Kostov K.; Effects of magnesium deficiency on mechanisms of insulin resistance in type 2 diabetes: Focusing on the processes of insulin secretion and signalling. Int J Mol Sci  2019,20(6),1351","journal-title":"Int J Mol Sci"},{"key":"ref=55","volume":"9","author":"Singh J.","year":"2017","unstructured":"Singh J.; Bidasee K.R.; Adeghate E.; Howarth C.F.; D\u2019Souza A.; Singh R.B.; Left ventricle structural remodelling in prediabetes and overt type 2 diabetes mellitus in the Goto-Kakizaki rat. World Heart J  2017,9(1)","journal-title":"World Heart J"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S2213-8587(23)00058-X","volume":"11","author":"Rubino F.","year":"2023","unstructured":"Rubino F.; Batterham R.L.; Koch M.; Mingrone G.; le Roux C.W.; Farooqi I.S.; Farpour-Lambert N.; Gregg E.W.; Cummings D.E.; Lancet diabetes and endocrinology commission on the definition and diagnosis of clinical obesity. Lancet Diabetes Endocrinol  2023,11(4),226-228","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"142245","DOI":"10.1172\/JCI142245","volume":"131","author":"Angelidi A.M.","year":"2021","unstructured":"Angelidi A.M.; Filippaios A.; Mantzoros C.S.; Severe insulin resistance syndromes. J Clin Invest  2021,131(4),142245","journal-title":"J Clin Invest"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1463-1326.2011.01453.x","volume":"13","author":"Thorens B.","year":"2011","unstructured":"Thorens B.; Brain glucose sensing and neural regulation of insulin and glucagon secretion. Diabetes Obes Metab  2011,13(s1),82-88","journal-title":"Diabetes Obes Metab"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1210\/jc.2007-1897","volume":"93","author":"Binder G.","year":"2008","unstructured":"Binder G.; Seidel A.K.; Martin D.D.; Schweizer R.; Schwarze C.P.; Wollmann H.A.; Eggermann T.; Ranke M.B.; The endocrine phenotype in silver-russell syndrome is defined by the underlying epigenetic alteration. J Clin Endocrinol Metab  2008,93(4),1402-1407","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1159\/000109323","volume":"1","author":"LeRoith D.","year":"1992","unstructured":"LeRoith D.; McGuinness M.; Shemer J.; Stannard B.; Lanau F.; Faria T.N.; Kato H.; Werner H.; Adamo M.; Roberts C.T.; Insulin-like growth factors. Neurosignals  1992,1(4),173-181","journal-title":"Neurosignals"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jcmgh.2018.10.016","volume":"7","author":"Santoleri D.","year":"2019","unstructured":"Santoleri D.; Titchenell P.M.; Resolving the paradox of hepatic insulin resistance. Cell Mol Gastroenterol Hepatol  2019,7(2),447-456","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.cmet.2016.04.022","volume":"23","author":"Titchenell P.M.","year":"2016","unstructured":"Titchenell P.M.; Quinn W.J.; Lu M.; Chu Q.; Lu W.; Li C.; Chen H.; Monks B.R.; Chen J.; Rabinowitz J.D.; Birnbaum M.J.; Direct hepatocyte insulin signaling is required for lipogenesis but is dispensable for the suppression of glucose production. Cell Metab  2016,23(6),1154-1166","journal-title":"Cell Metab"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"413","DOI":"10.4158\/EP15672.GL","volume":"21","author":"Handelsman Y.","year":"2015","unstructured":"Handelsman Y.; Bloomgarden Z.T.; Grunberger G.; Umpierrez G.; Zimmerman R.S.; Bailey T.S.; Blonde L.; Bray G.A.; Cohen A.J.; Dagogo-Jack S.; Davidson J.A.; Einhorn D.; Ganda O.P.; Garber A.J.; Garvey W.T.; Henry R.R.; Hirsch I.B.; Horton E.S.; Hurley D.L.; Jellinger P.S.; Jovanovi\u010d L.; Lebovitz H.E.; LeRoith D.; Levy P.; McGill J.B.; Mechanick J.I.; Mestman J.H.; Moghissi E.S.; Orzeck E.A.; Pessah-Pollack R.; Rosenblit P.D.; Vinik A.I.; Wyne K.; Zangeneh F.; American association of clinical endocrinologists and american college of endocrinology\u2013clinical practice guidelines for developing a diabetes mellitus comprehensive care plan\u20132015\u2014executive summary. Endocr Pract  2015,21(4),413-437","journal-title":"Endocr Pract"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2337\/dc13-2112","volume":"37","author":"Nathan D.M.","year":"2014","unstructured":"Nathan D.M.; The diabetes control and complications trial\/epidemiology of diabetes interventions and complications study at 30 years: Overview. Diabetes Care  2014,37(1),9-16","journal-title":"Diabetes Care"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4093\/dmj.2021.0280","volume":"46","author":"Lee S.H.","year":"2022","unstructured":"Lee S.H.; Park S.Y.; Choi C.S.; Insulin resistance: From mechanisms to therapeutic strategies. Diabetes Metab J  2022,46(1),15-37","journal-title":"Diabetes Metab J"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"98","DOI":"10.34172\/hpp.2020.18","volume":"10","author":"Mobasseri M.","year":"2020","unstructured":"Mobasseri M.; Shirmohammadi M.; Amiri T.; Vahed N.; Hosseini Fard H.; Ghojazadeh M.; Prevalence and incidence of type 1 diabetes in the world: A systematic review and meta-analysis. Health Promot Perspect  2020,10(2),98-115","journal-title":"Health Promot Perspect"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.pharma.2024.08.005","volume":"83","author":"Rajput S.","year":"2025","unstructured":"Rajput S.; Malviya R.; Srivastava S.; Ahmad I.; Rab S.O.; Uniyal P.; Cardiovascular disease and thrombosis: Intersections with the immune system, inflammation, and the coagulation system. Ann Pharm Fr  2025,83(2),228-250","journal-title":"Ann Pharm Fr"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"e938","DOI":"10.1542\/peds.2013-2795","volume":"133","author":"Dabelea D.","year":"2014","unstructured":"Dabelea D.; Rewers A.; Stafford J.M.; Standiford D.A.; Lawrence J.M.; Saydah S.; Imperatore G.; D\u2019Agostino R.B.; Mayer-Davis E.J.; Pihoker C.; Trends in the prevalence of ketoacidosis at diabetes diagnosis: The SEARCH for diabetes in youth study. Pediatrics  2014,133(4),e938-e945","journal-title":"Pediatrics"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.2337\/db07-1786","volume":"57","author":"Steck A.K.","year":"2008","unstructured":"Steck A.K.; Eisenbarth G.S.; Genetic similarities between latent autoimmune diabetes and type 1 and type 2 diabetes. Diabetes  2008,57(5),1160-1162","journal-title":"Diabetes"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1089\/dia.2020.0305","volume":"22","author":"Jacobsen L.M.","year":"2020","unstructured":"Jacobsen L.M.; Bundy B.N.; Greco M.N.; Schatz D.A.; Atkinson M.A.; Brusko T.M.; Mathews C.E.; Herold K.C.; Gitelman S.E.; Krischer J.P.; Haller M.J.; Comparing beta cell preservation across clinical trials in recent-onset type 1 diabetes. Diabetes Technol Ther  2020,22(12),948-953","journal-title":"Diabetes Technol Ther"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMra020100","volume":"347","author":"Bach J.F.","year":"2002","unstructured":"Bach J.F.; The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med  2002,347(12),911-920","journal-title":"N Engl J Med"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1046\/j.1464-5491.2001.00590-3.x","volume":"18","author":"Collado-Mesa F.","year":"2001","unstructured":"Collado-Mesa F.; Diaz-Diaz O.; Ashkenazi I.; Laron Z.; Seasonality of birth and Type 1 diabetes onset in children (0\u201314 years) in Cuba. Diabet Med  2001,18(11),939-940","journal-title":"Diabet Med"},{"key":"ref=73","first-page":"10","volume":"8","author":"Borba V.V.","year":"2020","unstructured":"Borba V.V.; Lerner A.; Matthias T.; Shoenfeld Y.; Bovine milk proteins as a trigger for autoimmune diseases: Myth or reality. Int J  2020,8(1),10-21","journal-title":"Int J"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1021\/acsnano.5b00028","volume":"9","author":"Shan W.","year":"2015","unstructured":"Shan W.; Zhu X.; Liu M.; Li L.; Zhong J.; Sun W.; Zhang Z.; Huang Y.; Overcoming the diffusion barrier of mucus and absorption barrier of epithelium by self-assembled nanoparticles for oral delivery of insulin. ACS Nano  2015,9(3),2345-2356","journal-title":"ACS Nano"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2011.12.055","volume":"425","author":"Wu Z.M.","year":"2012","unstructured":"Wu Z.M.; Zhou L.; Guo X.D.; Jiang W.; Ling L.; Qian Y.; Luo K.Q.; Zhang L.J.; HP55-coated capsule containing PLGA\/RS nanoparticles for oral delivery of insulin. Int J Pharm  2012,425(1-2),1-8","journal-title":"Int J Pharm"},{"key":"ref=76","first-page":"1748","volume":"24","author":"Bera S.","year":"2017","unstructured":"Bera S.; Naskar A.; Jana S.; Inorganic-organic hybrid nanocomposite for biomedical applications. Adv Mater  2017,24(13),1748-1754","journal-title":"Adv Mater"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.msec.2016.08.083","volume":"70","author":"Li L.","year":"2017","unstructured":"Li L.; Jiang G.; Yu W.; Liu D.; Chen H.; Liu Y.; Tong Z.; Kong X.; Yao J.; Preparation of chitosan-based multifunctional nanocarriers overcoming multiple barriers for oral delivery of insulin. Mater Sci Eng C  2017,70(Pt 1),278-286","journal-title":"Mater Sci Eng C"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"105102","DOI":"10.1088\/0957-4484\/18\/10\/105102","volume":"18","author":"Lin Y.H.","year":"2007","unstructured":"Lin Y.H.; Chen C.T.; Liang H.F.; Kulkarni A.R.; Lee P.W.; Chen C.H.; Sung H.W.; Novel nanoparticles for oral insulin delivery via the paracellular pathway. Nanotechnology  2007,18(10),105102","journal-title":"Nanotechnology"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ijbiomac.2022.01.134","volume":"203","author":"Sabbagh F.","year":"2022","unstructured":"Sabbagh F.; Muhamad I.I.; Niazmand R.; Dikshit P.K.; Kim B.S.; Recent progress in polymeric non-invasive insulin delivery. Int J Biol Macromol  2022,203,222-243","journal-title":"Int J Biol Macromol"},{"key":"ref=80","doi-asserted-by":"publisher","DOI":"10.1201\/9781003573715","author":"Lee V., Ed.;","year":"2024","unstructured":"Lee V., Ed.;;  Peptide and protein drug delivery  2024","journal-title":"Peptide and protein drug delivery"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3945\/jn.110.135657","volume":"141","author":"Ulluwishewa D.","year":"2011","unstructured":"Ulluwishewa D.; Anderson R.C.; McNabb W.C.; Moughan P.J.; Wells J.M.; Roy N.C.; Regulation of tight junction permeability by intestinal bacteria and dietary components. J Nutr  2011,141(5),769-776","journal-title":"J Nutr"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.ijpharm.2004.12.025","volume":"293","author":"Ma Z.","year":"2005","unstructured":"Ma Z.; Lim T.M.; Lim L.Y.; Pharmacological activity of peroral chitosan\u2013insulin nanoparticles in diabetic rats. Int J Pharm  2005,293(1-2),271-280","journal-title":"Int J Pharm"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1021\/ar200234q","volume":"45","author":"Sung H.W.","year":"2012","unstructured":"Sung H.W.; Sonaje K.; Liao Z.X.; Hsu L.W.; Chuang E.Y.; pH-responsive nanoparticles shelled with chitosan for oral delivery of insulin: From mechanism to therapeutic applications. Acc Chem Res  2012,45(4),619-629","journal-title":"Acc Chem Res"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3109\/02652040903515490","volume":"27","author":"Sun S.","year":"2010","unstructured":"Sun S.; Liang N.; Piao H.; Yamamoto H.; Kawashima Y.; Cui F.; Insulin-S.O (sodium oleate) complex-loaded PLGA nanoparticles: Formulation, characterization and in vivo evaluation. J Microencapsul  2010,27(6),471-478","journal-title":"J Microencapsul"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/jps.20750","volume":"96","author":"Cui F.","year":"2007","unstructured":"Cui F.; Tao A.; Cun D.; Zhang L.; Shi K.; Preparation of insulin loaded PLGA-Hp55 nanoparticles for oral delivery. J Pharm Sci  2007,96(2),421-427","journal-title":"J Pharm Sci"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jconrel.2006.12.003","volume":"117","author":"Chalasani K.B.","year":"2007","unstructured":"Chalasani K.B.; Russell-Jones G.J.; Yandrapu S.K.; Diwan P.V.; Jain S.K.; A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin. J Control Release  2007,117(3),421-429","journal-title":"J Control Release"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"101405","DOI":"10.1016\/j.nanoso.2024.101405","volume":"40","author":"Rajput S.","year":"2024","unstructured":"Rajput S.; Malviya R.; Sridhar S.B.; Nanoparticle-based photodynamic therapy for targeted treatment of breast cancer. Nano Struct Nano Objects  2024,40,101405","journal-title":"Nano Struct Nano Objects"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"5290","DOI":"10.1002\/jps.21347","volume":"97","author":"Reis C.P.","year":"2008","unstructured":"Reis C.P.; Veiga F.J.; Ribeiro A.J.; Neufeld R.J.; Damg\u00e9 C.; Nanoparticulate biopolymers deliver insulin orally eliciting pharmacological response. J Pharm Sci  2008,97(12),5290-5305","journal-title":"J Pharm Sci"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.ejps.2010.08.009","volume":"41","author":"Woitiski C.B.","year":"2010","unstructured":"Woitiski C.B.; Neufeld R.J.; Veiga F.; Carvalho R.A.; Figueiredo I.V.; Pharmacological effect of orally delivered insulin facilitated by multilayered stable nanoparticles. Eur J Pharm Sci  2010,41(3-4),556-563","journal-title":"Eur J Pharm Sci"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ejps.2008.12.017","volume":"37","author":"Graf A.","year":"2009","unstructured":"Graf A.; Rades T.; Hook S.M.; Oral insulin delivery using nanoparticles based on microemulsions with different structure-types: Optimisation and in vivo evaluation. Eur J Pharm Sci  2009,37(1),53-61","journal-title":"Eur J Pharm Sci"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/(SICI)1438-9312(200002)102:2<133:AID-EJLT133>3.0.CO;2-X","volume":"102","author":"Beisson F.","year":"2000","unstructured":"Beisson F.; Tiss A.; Rivi\u00e8re C.; Verger R.; Methods for lipase detection and assay: A critical review. Eur J Lipid Sci Technol  2000,102(2),133-153","journal-title":"Eur J Lipid Sci Technol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1248\/bpb.29.1790","volume":"29","author":"Rawat M.","year":"2006","unstructured":"Rawat M.; Singh D.; Saraf S.; Saraf S.; Nanocarriers: Promising vehicle for bioactive drugs. Biol Pharm Bull  2006,29(9),1790-1798","journal-title":"Biol Pharm Bull"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ijpharm.2006.07.026","volume":"327","author":"Zhang N.","year":"2006","unstructured":"Zhang N.; Ping Q.; Huang G.; Xu W.; Cheng Y.; Han X.; Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int J Pharm  2006,327(1-2),153-159","journal-title":"Int J Pharm"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3109\/03639045.2010.497151","volume":"37","author":"Yang R.","year":"2011","unstructured":"Yang R.; Gao R.; Li F.; He H.; Tang X.; The influence of lipid characteristics on the formation, in vitro release, and in vivo absorption of protein-loaded SLN prepared by the double emulsion process. Drug Dev Ind Pharm  2011,37(2),139-148","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ijpharm.2009.10.018","volume":"385","author":"Mora-Huertas C.E.","year":"2010","unstructured":"Mora-Huertas C.E.; Fessi H.; Elaissari A.; Polymer-based nanocapsules for drug delivery. Int J Pharm  2010,385(1-2),113-142","journal-title":"Int J Pharm"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1080\/10611860701603372","volume":"15","author":"Vauthier C.","year":"2007","unstructured":"Vauthier C.; Labarre D.; Ponchel G.; Design aspects of poly(alkylcyanoacrylate) nanoparticles for drug delivery. J Drug Target  2007,15(10),641-663","journal-title":"J Drug Target"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1080\/08927022.2019.1609671","volume":"45","author":"Shin E.","year":"2019","unstructured":"Shin E.; Joo S.H.; Yeom M.S.; Kwak S.K.; Theoretical study on the stability of insulin within poly-isobutyl cyanoacrylate (PIBCA) nanocapsule. Mol Simul  2019,45(11),896-903","journal-title":"Mol Simul"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/jbm.b.30372","volume":"76B","author":"Sajeesh S.","year":"2006","unstructured":"Sajeesh S.; Sharma C.P.; Novel pH responsive polymethacrylic acid\u2013chitosan\u2013polyethylene glycol nanoparticles for oral peptide delivery. J Biomed Mater Res B Appl Biomater  2006,76B(2),298-305","journal-title":"J Biomed Mater Res B Appl Biomater"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"217","DOI":"10.25122\/jml-2023-0355","volume":"17","author":"Abd-Alhussain G.K.","year":"2024","unstructured":"Abd-Alhussain G.K.; Alatrakji M.Q.Y.M.A.; Ahmed S.J.; Fawzi H.A.; Efficacy of oral insulin nanoparticles for the management of hyperglycemia in a rat model of diabetes induced with streptozotocin. J Med Life  2024,17(2),217-225","journal-title":"J Med Life"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jconrel.2006.10.023","volume":"117","author":"Damg\u00e9 C.","year":"2007","unstructured":"Damg\u00e9 C.; Maincent P.; Ubrich N.; Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J Control Release  2007,117(2),163-170","journal-title":"J Control Release"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/B978-0-443-15401-0.00010-5","author":"Gupta S.","year":"2024","unstructured":"Gupta S.; Tejavath KK.; Poly(alkyl cyanoacrylate): Advancement as nano delivery systems. Cancer Therapy  2024,253-265","journal-title":"Cancer Therapy"},{"key":"ref=102","doi-asserted-by":"publisher","DOI":"10.2174\/0113816128358473250331175536","author":"Rana A.","year":"2025","unstructured":"Rana A.; Mittal A.; Vashist C.; Rajput S.; Sridhar S.B.; Malviya R.; Exploration of 4D printing and its applications in the biomedical sciences. Curr Pharm Des  2025","journal-title":"Curr Pharm Des"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1007\/s11095-007-9367-4","volume":"24","author":"Sarmento B.","year":"2007","unstructured":"Sarmento B.; Ribeiro A.; Veiga F.; Sampaio P.; Neufeld R.; Ferreira D.; Alginate\/chitosan nanoparticles are effective for oral insulin delivery. Pharm Res  2007,24(12),2198-2206","journal-title":"Pharm Res"},{"key":"ref=104","author":"Wilkinson R.G.","year":"2003","unstructured":"Wilkinson R.G.; Marmot M.;  Social determinants of health: The solid facts  2003","journal-title":"Social determinants of health: The solid facts"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"163","DOI":"10.4093\/dmj.2014.38.3.163","volume":"38","author":"Kern T.S.","year":"2014","unstructured":"Kern T.S.; Interrelationships between the retinal neuroglia and vasculature in diabetes. Diabetes Metab J  2014,38(3),163-170","journal-title":"Diabetes Metab J"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.2174\/09298673113209990027","volume":"20","author":"Stem M.","year":"2013","unstructured":"Stem M.; Gardner T.; Neurodegeneration in the pathogenesis of diabetic retinopathy: Molecular mechanisms and therapeutic implications. Curr Med Chem  2013,20(26),3241-3250","journal-title":"Curr Med Chem"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.3390\/ijms15021865","volume":"15","author":"Payne A.","year":"2014","unstructured":"Payne A.; Kaja S.; Naumchuk Y.; Kunjukunju N.; Koulen P.; Antioxidant drug therapy approaches for neuroprotection in chronic diseases of the retina. Int J Mol Sci  2014,15(2),1865-1886","journal-title":"Int J Mol Sci"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/s12031-015-0561-2","volume":"56","author":"Ola M.S.","year":"2015","unstructured":"Ola M.S.; Ahmed M.M.; Ahmad R.; Abuohashish H.M.; Al-Rejaie S.S.; Alhomida A.S.; Neuroprotective effects of rutin in streptozotocin-induced diabetic rat retina. J Mol Neurosci  2015,56(2),440-448","journal-title":"J Mol Neurosci"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"300","DOI":"10.12659\/MSM.883895","volume":"19","author":"Ola M.S.","year":"2013","unstructured":"Ola M.S.; Abouammoh M.; Khan H.A.; Alhomida A.S.; Alfaran M.F.; Ola M.S.; Novel drugs and their targets in the potential treatment of diabetic retinopathy. Med Sci Monit  2013,19,300-308","journal-title":"Med Sci Monit"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113895575398397250827102455","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/245325\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113895575398397250827102455","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T05:50:48Z","timestamp":1764568248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/245325\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":109,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113895575398397250827102455","relation":{},"ISSN":["1389-5575"],"issn-type":[{"type":"print","value":"1389-5575"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-03-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}